BCM
RVNC

Bayesian Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bayesian Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-83,500
Closed -$433K – 1059
2024
Q3 		$433K Buy
+83,500
New +$415K 0.05% 407
2022
Q3 		– Sell
-18,700
Closed -$258K – 1072
2022
Q2 		$258K Buy
18,700
+3,900
+26% +$60K 0.05% 532
2022
Q1 		$289K Buy
+14,800
New +$224K 0.04% 537

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Bayesian Capital Management's RVNC Position: Q4 2024 in Review

Bayesian Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 83,500 shares — an estimated $433K sold.

Bayesian Capital Management first reported a position in RVNC in Q1 2022 and held it in 3 quarters. The position peaked at $433K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Bayesian Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 83,500 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $433K.
  • Bayesian Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Revance Therapeutics, Inc. position peaked at $433K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.